The biotechnology company Novavax plans to submit complete data to the FDA soon for possible emergency use authorization of its coronavirus vaccine, CEO Stanley Erck told CNN in a phone interview Friday. … If the FDA gives the green light, the first 100 million doses of the protein-based vaccine will be ready to ship following authorization, Erck said.